Procedure for Stability Testing of Biosimilars According to WHO Guidelines
1) Purpose
The purpose of this SOP is to establish a procedure for conducting stability testing for biosimilar products in accordance with the World Health Organization (WHO) guidelines. This ensures that biosimilars maintain their safety, quality, and efficacy throughout their shelf life and meet global regulatory standards.
2) Scope
This SOP applies to all personnel involved in the stability testing of biosimilar products, including those in quality control, product development, and regulatory affairs teams.
3) Responsibilities
Product Development Team: Responsible for developing biosimilar formulations and selecting appropriate packaging.
Stability Study Team: Responsible for designing and conducting stability studies in line with WHO guidelines.
Regulatory Affairs Team: Responsible for ensuring that all stability data meets WHO requirements and is prepared for regulatory submissions.
4) Procedure
4.1 Development of Stability Testing Protocol
4.1.1 Create a stability testing protocol
4.1.2 Define the required storage conditions (e.g., refrigerated, frozen) and establish testing intervals (e.g., 0, 3, 6, 12 months) based on WHO guidelines.
4.2 Sample Preparation and Storage
4.2.1 Prepare samples in their final packaging format, ensuring that packaging integrity
4.2.2 Store samples under the specified conditions, utilizing validated storage equipment, and monitor environmental conditions continuously.
4.3 Conducting Stability Testing
4.3.1 Perform stability tests at each defined interval, including assessments of physical, chemical, and biological properties, as well as any degradation markers.
4.3.2 Ensure all data is accurately recorded, following good documentation practices (GDP) to maintain data integrity.
4.4 Data Analysis and Reporting
4.4.1 Analyze stability data to identify trends, deviations, or out-of-specification results that could impact product quality or safety.
4.4.2 Compile a comprehensive stability report with all findings, analyses, and conclusions, and prepare it for submission to the appropriate regulatory authorities as per WHO guidelines.
5) Abbreviations, if any
WHO: World Health Organization
GDP: Good Documentation Practices
6) Documents, if any
6.1 WHO biosimilar stability testing guidelines
6.2 Stability testing protocols
6.3 Raw data sheets
6.4 Comprehensive stability reports
7) Reference, if any
WHO Guidelines on the Evaluation of Similar Biotherapeutic Products (SBPs), Stability Testing Requirements
8) SOP Version
Version 1.0